School of Medicine

Laura Gray


Full Name: Dr Laura Gray
Position Title: Lecturer in Molecular Neurobiology
Telephone: +61 3 522 72852
Email: l.gray@deakin.edu.au
Campus: Geelong at Waurn Ponds
laura gray

 

Research overview

Psychiatric and neurological disorders represent an enormous contribution to the burden of disability worldwide, and the extension of life expectancy and aging population is likely to expand this problem in coming years. Research into the mechanisms and treatment of neuropsychiatric disease is a priority in Australia and internationally.
Dr Gray has a particular interest in the in the intersections between neurodevelopmental, neurodegenerative and psychiatric disorders and how these diseases dysregulate fundamental neurobiology. Dysfunction of stress signalling, oxidative and inflammatory pathways will be examined, and how these influence the trans-synaptic circuits regulating neurotransmitter synthesis, release and reuptake. Studies of mechanistic neurobiology are linked closely to behaviour, brain function and mood.
Research in this group will extend from molecular biology and neurochemistry to neuropharmacology and behavioural assays, with a particular focus on current and developmental therapeutics for neuropsychiatric disease.

 

Biography

Dr Gray was awarded her PhD from the University of Melbourne and the Mental Health Research Institute, studying neurotransmitter and growth factor dysregulation in schizophrenia and bipolar disorder. She conducted postdoctoral research into animal models of neuropsychiatric disease, neuropharmacology and gene-environment interactions at the Florey Neuroscience Institute, before joining the Duke-NUS Graduate Medical School in Singapore as a Research Fellow. There she examined behavioural and cellular models of stress-serotonin interactions in depression, in addition to studies of the fundamental regulation of monoamine synthesis in the brain. Dr Gray is currently a lecturer in the School of Medicine at Deakin University, and is the coordinator of the Brain and Behaviour unit for pre-clinical medical students.

 

Dr Laura Gray's Publications

  1. Gray, L., Hannan, A, Zhang, X., Metabotropic glutamate receptors as targets for novel antipsychotic treatments, Current Pharmaceutical Biotechnology (invited review, in press).

  2. Gray, L., Dean, B., Kronsbein, H., Robinson, P., Scarr, E., Region and diagnosis specific changes in synaptic proteins in schizophrenia and bipolar I disorder, Psychiatry Research (2010) 178(2) 374-380.

  3. Gray, L., McOmish, C., Scarr, E., Dean, B, Hannan, A., Sensitivity to the psychotomimetic MK-801 in phospholipase C-ß1 knockout mice reveals a specific NMDA receptor deficit, International Journal of Neuropsychopharmacology, (2009) 12(7) 917-928.

  4. Gray, L., Scarr, E., Dean, B, van den Buuse, M, Hannan, A., Clozapine reverses schizophrenia-related behaviours in the mGluR5 knockout mouse: involvement of the NMDA receptor, International Journal of Neuropsychopharmacology, (2009) 12(1), 45-60.

  5. Kondo, M., Gray, L., Pelka, G., Christodoulou, J., Tam, PPL., Hannan, A., Motor and BDNF deficits in a Rett syndrome mouse model are ameliorated by environmental enrichment, European Journal of Neuroscience, (2008) 27(12), 3342-50.

  6. Gray, L., McOmish, C., A.J. Hannan., Role of muscarinic receptors in the activity of N-desmethylclozapine; reversal of hyperactivity in phospholipase C-ß1 knockout mice, Behavioural Pharmacology, (2008) 19(5-6), 543-7.

  7. Gray, L., Hannan, A., Dissecting cause and effect in the pathogenesis of psychiatric disorders - genes, environment and behaviour, (review article)Current Molecular Medicine, (2007) 7(5): 470-8.

 

 

 

Deakin University acknowledges the traditional land owners of present campus sites.

25th November 2011